The choice of ANXA2 as a biomarker was based on previous reports that high ANXA2 levels are strongly correlated to the survival of pancreatic cancer patients, which was also verified by our bioinformatical study [12, 23]. This evidence concerns the gene ANXA2 and pancreatic neoplasm.